[{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","commit":"ad64caf371","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fifth batch of approved products","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Relatlimab\" }]"}]},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"tldr","before":"\"The first drug targeting the LAG-3 immune brake, given with nivolumab for melanoma.\"","after":"\"Opdualag combines relatlimab, the first drug targeting the LAG-3 immune brake, with nivolumab for melanoma.\""}]}]